Eton Pharmaceuticals Inc. (ETON) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Eton Pharmaceuticals Inc. (ETON:NASDAQ), powered by AI.

Current Price
$46.46
P/E Ratio
-286.7
Market Cap
1.3B
Sector
Healthcare
What is the Eton Pharmaceuticals Inc. stock price forecast?

Eton Pharmaceuticals Inc. is currently trading at $46.46. View real-time AI analysis on Alpha Lenz.

What is Eton Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Eton Pharmaceuticals Inc. on Alpha Lenz.

What is Eton Pharmaceuticals Inc.'s P/E ratio?

Eton Pharmaceuticals Inc.'s P/E ratio is -286.7.

Eton Pharmaceuticals Inc.

NASDAQ · ETON
$46.46-2.57(-5.24%)LiveNASDAQ regular session 09:30–16:00 ET
Ask about Eton Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Eton Pharmaceuticals Inc. trades at a P/E of -286.7 (undervalued) with modest ROE of -18.2%. 3Y revenue CAGR of 55.5% highlights clear growth momentum.

Ask for details

Company Overview

Eton Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative prescription products. Its primary function is to address unmet needs in the pharmaceutical landscape, particularly targeting rare diseases and niche therapy areas. Eton's strategy revolves around reformulating and enhancing existing drugs for better efficacy, safety, and patient compliance. The company's portfolio includes products across various medical fields, such as endocrinology, oncology, and neurology, enhancing the lives of patients with conditions often overlooked by larger pharmaceutical firms. Established in the United States, Eton Pharmaceuticals plays a crucial role in the healthcare sector by providing solutions that may not receive significant attention from larger players in the market. Through strategic partnerships and a focus on underserved patient populations, Eton contributes to the diversification and innovation of treatment options available in the pharmaceutical industry.

CEOMr. Sean E. Brynjelsen
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees31

Company Statistics

FY 2025

Profile

$1.32BMarket Cap
$79.95MRevenue
0.00Shares Out
31Employees

Margins

53.46%Gross
4.00%EBITDA
-1.06%Operating
-5.70%Pre-Tax
-5.75%Net

Valuation

-286.74P/E
50.44P/B
16.50EV/Sales
413.87EV/EBITDA
129.46P/FCF

Growth (CAGR)

55.53%Rev 3Yr
359.57%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-5.47%ROA
-18.19%ROE
-1.00%ROIC

Financial Health

$25.94MCash & Cash Equivalents
$40.02MNet Debt
252.20%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Eton Pharmaceuticals Inc. (ticker: ETON) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 31 employees. Market cap is $1.3B.

The current price is $46.46 with a P/E ratio of -286.74x and P/B of 50.44x.

ROE is -18.19% and operating margin is -1.06%. Annual revenue is $80M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Eton Pharmaceuticals Inc. (ETON) Stock Forecast 2026 $46.46 — Price, Financials & Analyst Targets | Alpha Lenz